Mesoblast Shares Rise 9.5% as Phase 3 Patient Treatment Completes for Chronic Low Back Pain

MESO Mesoblast Ltd ADR

$13.94 +2.42%

View chart & analysis →

EYPT +4.73% REGN +0.46% NNVC +2.86%

1. 1Mesoblast (MESO) shares climbed 9.5% after the company completed patient treatment in the Phase 3 trial of its chronic low back pain therapy rexlemestrocel-L
2. 2In MSB-DR004, 350 patients were randomized to receive a single intradiscal injection or a sham injection, expanded from the originally planned 300
3. 3The primary endpoint is confirmation of sustained pain reduction at 12 months, with topline results expected in mid-2027 after final patient follow-up

Source InvestorsHub +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →